Clearmind Medicine (CMND) Other Non-Current Liabilities (2021 - 2026)
Clearmind Medicine (CMND) posted quarterly Other Non-Current Liabilities of $2.1 million for Q2 2026, down 7.87% year-over-year from $2.3 million in Q2 2025, and up 21.58% quarter-over-quarter from $1.8 million in Q1 2026.
Clearmind Medicine (CMND) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Clearmind Medicine's Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $2.1 million for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities fell 7.87% year-over-year to $2.1 million; the TTM figure through Apr 2026 stood at $2.1 million (down 7.87% YoY), while the FY2025 annual figure was $2.4 million, down 32.69% from the prior year.
- Other Non-Current Liabilities for Q2 2026 stood at $2.1 million, up from $1.8 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $4.3 million in Q3 2024, with the low at $667901.5 in Q1 2023.
- The 5-year median for Other Non-Current Liabilities is $2.2 million (2025), against an average of $2.5 million.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities surged 417.27% in 2022, then plunged 49.5% in 2025.
- Clearmind Medicine's Other Non-Current Liabilities stood at $1.4 million in 2022, then surged by 200.26% to $4.3 million in 2023, then slipped by 18.34% to $3.5 million in 2024, then slumped by 32.69% to $2.4 million in 2025, then decreased by 9.85% to $2.1 million in 2026.
- Business Quant data shows CMND's Other Non-Current Liabilities at $2.1 million in Q2 2026, $1.8 million in Q1 2026, and $2.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Clearmind Medicine | 540,485.35 | -13.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.14 Mn |
| Jan 31, 2026 | 1.76 Mn |
| Oct 31, 2025 | 2.37 Mn |
| Jul 31, 2025 | 2.18 Mn |
| Apr 30, 2025 | 2.32 Mn |
| Jan 31, 2025 | 2.98 Mn |
| Oct 31, 2024 | 3.52 Mn |
| Jul 31, 2024 | 4.31 Mn |
| Apr 30, 2024 | 3.73 Mn |
| Oct 31, 2023 | 4.31 Mn |
| Jul 31, 2023 | 1.31 Mn |
| Apr 30, 2023 | 1.80 Mn |
| Jan 31, 2023 | 667,901.47 |
| Oct 31, 2022 | 1.44 Mn |
| Oct 31, 2021 | 277,524.26 |